OncoQuest, Tesaro Team Up to Test Oregovomab-Zejula Combo

OncoQuest, Tesaro Team Up to Test Oregovomab-Zejula Combo
OncoQuest has entered into a collaborative agreement with Tesaro to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab (MAb B43.13) with Zejula (niraparib) in recurrent ovarian cancer. Oregovomab is a high-affinity monoclonal antibody designed to bind to the tumor-associated antigen CA125 and initiate a cascade of immune responses against this protein. CA125 is expressed

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *